Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies (“Theranostics”) to target cancer first at the “diagnosis” phase and then at the “therapy” phase, using the same biological targets (“see to treat”).
FDA Staff Cast Doubt on Novel Drug for MDS-Related Anemia
FDA staff appear to have serious doubts about the prospects of imetelstat as a treatment for transfusion-dependent anemia in adults with myelodysplastic syndromes (MDS), according
March 13, 2024